Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3306397 | 0.95 | — | — | |
| Iodide SCHEMBL8945711 | 0.90 | — | — | |
| SCHEMBL8757170 | 0.79 | — | — | |
| SCHEMBL14959935 | 0.67 | — | — | |
| SCHEMBL777009 | 0.67 | — | — | |
| Propene SCHEMBL27518964 | 0.56 | — | — | |
| Propene SCHEMBL27717900 | 0.56 | — | — | |
| SCHEMBL10403961 | 0.56 | — | — | |
| Propene SCHEMBL11543442 | 0.53 | — | — | |
| Propene SCHEMBL193 | 0.52 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060018914-A1 | Novel antibody conjugates reactive with human carcinomas | BRISTOL-MYERS SQUIBB COMPANY | 2006-01-26 | — | — | US | disclosed |
| US-20040043029-A1 | Novel antibodies reactive with human carcinomas | BRISTOL-MYERS SQUIBB COMPANY | 2004-03-04 | — | — | US | disclosed |
| US-20020192223-A1 | Novel antibody conjugates reactive with human carcinomas | HELLSTROM INGEGERG (US) | 2002-12-19 | — | — | US | disclosed |
| US-6020145-A | Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-02-01 | — | — | US | disclosed |
| US-5980896-A | Antibodies reactive with human carcinomas | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-11-09 | — | — | US | disclosed |
| US-5869045-A | POLYPEPTIDE COMPRISING ANTIGEN-BINDING REGION OF MONOCLONAL ANTIBODY PRODUCED BY SPECIFIED HYBRIDOMA | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-02-09 | — | — | US | disclosed |
| US-5708146-A | ANTIBODIES AND DRUGS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-01-13 | — | — | US | disclosed |
| US-5622929-A | ANTHRACYCLINE ANTIBIOTIC; ANTITUMOR AGENT BINDS WITH A TARGET CELL | BRISTOL-MYERS SQUIBB COMPANY (US) | 1997-04-22 | — | — | US | disclosed |
| US-5606017-A | ANTITUMOR AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1997-02-25 | — | — | US | disclosed |
| EP-0554708-A1 | Thioether conjugates | Bristol-Myers Squibb Company (US) | 1993-08-11 | — | — | EP | disclosed |